# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 8, 2026**

## INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

| **Delaware** | **0-26224** | **51-0317849** |
|---|---|---|
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |

**1100 Campus Road**
**Princeton, NJ 08540**
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: **(609) 275-0500**

**Not Applicable**
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities Registered Pursuant to Section12(b) of the Act:

| **Title of Each Class** | **Trading Symbol** | **Name of Exchange on Which Registered** |
|---|---|---|
| Common Stock, Par Value $.01 Per Share | IART | Nasdaq Global Select Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

Integra LifeSciences Holdings Corporation (the "Company") hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use, from time to time, in presentations to existing or prospective lenders in connection with the Company's previously-disclosed plans to refinance its outstanding senior credit facility in 2026.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

99.1 Investor Presentation, dated September 8, 2026

104 Cover Page Interactive Data File (embedded within the inline XRBL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: September 8, 2026

By: /s/ Lea Knight
Lea Knight
Title: Executive Vice President and Chief Financial Officer

*These materials are not to be printed, downloaded or distributed.*
*These materials are only available to QIBs and non-US persons.*

# Investor Presentation

September 2026

*This presentation includes information that (i) is publicly available (or could be derived from publicly available information) and (ii) does not constitute material nonpublic information with respect to the company, its subsidiaries or its or their respective securities.*

INTEGRA

# Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may," "could," "would," "might," "possible," "should," "expect," "intend," "forecast," "guidance," "plan," "anticipate," "target," or "continue," the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this presentation include, but are not limited to, statements concerning: the future business, operational and financial performance of the Company and the Company's expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company's compliance master plan to improve the Company's quality systems. It is important to note that the Company's goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, the following: increased geopolitical tension, instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, supply chain disruptions, and interest rate and foreign currency rate fluctuations on the Company's suppliers, vendors and customers and on the Company's business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company's compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs there of potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the Company's ongoing assessment of the flooding event at its Cincinnati, Ohio manufacturing facility, related financial impacts, recovery efforts, potential assets impairments, unforeseen costs and insurance recoveries; the failure of the company's suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company's products in these markets; the Company's ability to predict accurately the demand for its products, and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward healthcare cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company's products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global healthcare reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors' or customers' information technology systems or products; the potential impact of our compliance with governmental regulations and accounting guidance; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission.

These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.

# Non-GAAP Financial Measures

In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, free cash flow and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted EBITDA margin is calculated by dividing adjusted EBITDA by GAAP revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to the transition of Boston-related manufacturing operations to the Company's Braintree, Massachusetts facility; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.

Reconciliations of (i) GAAP net income to adjusted EBITDA for the years ended December 31, 2025, 2024, 2023, 2022 and 2021, and for the four quarters and last twelve months ended June 30 2026, (ii) GAAP gross profit to adjusted gross profit, GAAP gross margin to adjusted gross margin, and GAAP operating cash flow to free cash flow for the years ended December 31, 2025, 2024, 2023, 2022 and 2021, and for the last twelve months ended June 30 2026, appear in the Appendix in this presentation.

The Company believes that the presentation of non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations.

No Offer

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any security, and shall not form the basis of any contract. Any offering of securities will be made solely by means of a separate offering memorandum or other definitive offering document and in accordance with applicable securities laws.

# Executive summary

- **Integra Lifesciences Holdings Corporation ("Integra" or the "Company") is a global MedTech leader that engages in the manufacture and sale of medical devices specializing in neurosurgery and regenerative tissue repair through its two segments:**
  - Specialty Surgery: provides neurosurgical and neurocritical care devices used across the continuum of care—from pre-operative planning and intraoperative neurosurgery to post-operative critical care—for adult and pediatric patients with traumatic brain injury, hydrocephalus, cerebrovascular conditions, brain tumors, and select ENT related disorders
  - Tissue Reconstruction: provides collagen-based and regenerative tissue technologies used in the treatment of acute and chronic wounds, burns, and surgical tendon and ligament repair
- **Integra views 2026 as a key inflection period as it progresses through FDA-mandated manufacturing / quality system remediations, with several operational tailwinds expected to support future growth**
  - All warning letter commitments on track to be completed in 2026
  - SurgiMend expected to relaunch in Q4 2026
  - New state-of-the-art manufacturing site in Braintree, MA ("Braintree") became operational in Q2 2026; on track for commercial revenue being generated in Q4 2026
  - Remaining remediation / compliance spend expected to decrease
- **Key financials highlights**
  - LTM Q2 2026 revenue of $1,648M, up 1.6% YoY, and Adjusted EBITDA of $337M, up 11.8% YoY, representing a 20.5% margin
  - YoY FCF growth of $57M



01

# Business overview

INTEGRA

# A global MedTech leader dedicated to restoring lives

**$1.6B**
LTM reported revenue

**62.5%**
LTM adjusted gross margin

**20.5%**
LTM adjusted EBTIDA margin

**$85M**
LTM operating cash flow

- Global player with leading positions in neurosurgery and regenerative medicine
- Large and growing addressable markets
- Diversified portfolio across neurosurgery, reconstructive, and general surgical specialties
- Strong clinical brand equity and surgeon loyalty supported by differentiated product performance and clinical evidence
- Clear and methodical remediation plan well underway and supported by significant investment
- At key inflection point with visibility to return to strong FCF generation and deleveraging
- Seasoned leadership team with decades of MedTech experience

Financial metrics shown for the trailing 12-months ended Jun. 30, 2026
Both adj. gross margin and adj. EBITDA margin are non-GAAP financial measures; See appendix for non-GAAP reconciliations

# Evolution of Integra: Building a scaled specialty platform




***M&A growth and organic revenue generation backed by a disciplined track record of deleveraging post-M&A via FCF generation and select equity issuance***

# Where we play

## Leading player in attractive, niche markets through focus

**Specialty surgical, neurological and regenerative care**

TAM: ~$9.0B[1]

MSD growth

### Specialty Surgery

Procedure-driven surgical tools and implants across neuro, instruments, and ENT

TAM: ~$6.0B

MSD growth

Revenue: $1.2B[2]

### Tissue Reconstruction

Regenerative products for wound and burn healing, management and repair as well as general surgery

TAM: ~$2.5B[1]

MSD – HSD growth

Revenue: $0.4B[2]

[1] TAM excludes private label markets; [2] LTM revenue as of 06/30/26

# How we play

## Leadership in attractive, niche markets though differentiated technologies and commercial excellence

### OUR ADVANTAGED POSITION

- **Unique focus** and **#1-2 player in** attractive markets
- **Depth and breadth** of portfolio and technologies
- **Tenured, trusted salesforce** and channels
- **Global footprint** for technology access and commercialization
- **Flexible balance sheet** with disciplined capital management
- **Organic and inorganic innovation** aimed at accretive growth segments

**Growing patient population** in chronic disease and emerging markets

**Differentiated technologies and innovation** matter

**Attractive high growth niche opportunities** in core markets

**Surgeons have higher influence** in product decisions

# Building the foundation for sustainable growth

## Focused execution enabling innovation and growth




[1] CMS refers to skin substitute as CTP = Cell & Tissue-Based Products

# Delivering our vision in 2026 and beyond

## Build a culture of quality and execution excellence, solidify market leadership, drive company performance



02

# Specialty Surgery

INTEGRA

# Specialty Surgery overview

## Established leadership in served markets, portfolio positioned to maintain stable market growth

**~$6B** Market[1]

**>$1B** Revenue[2]

### NEURO
MSD Market CAGR

**BRAIN LESION SURGERY WITH MIS EXPANSION**

**Dural Access & Repair**

*DuraGen Dural Graft*
*DuraSeal Dural Sealant*

**Advanced Energy**

*CUSA Tissue Ablation*
*Aurora® Surgiscope*

**ACUTE BRAIN INJURY**

**Neurocritical Care**

*CereLink® ICP Monitor and Sensors*

**HYDROCEPHALUS**

**Hydrocephalus**

*Certas Plus Programmable Valves • BACTISEAL® Catheters*

### ENT
MSD Market CAGR

**ENT**

**ENT**

*TruDi® • RELIEVA SPINPLUS® NAV • AERA®•MicroFrance®*

### INSTRUMENTS
LSD Market CAGR

**NEURO AND SPECIALTY INSTRUMENTATION**

**Instruments**

*Jarit® • Surgical Lighting Systems*

Note: Market size and growth from third party market reports and internal estimates; [1] TAM for ENT is US only; [2] LTM revenue as of 06/30/26; MIS = Minimally Invasive Surgery; ICP = Increased Intracranial Pressure

# Neuro

## Comprehensive portfolio of high-utilization products that underpin neurosurgery procedures

**DuraGen® Dural Graft Matrix**

Absorbable dural graft matrix for sutureless repair of dural defects

**DuraSeal® Dural Sealant System**

Hydrogel sealant to provide watertight closure around suture lines

**BACTISEAL® Catheters**

Antibiotic-impregnated catheter to reduce CSF infection risk

**CUSA® Clarity**

Platform used for fragmentation and aspiration of soft and hard tissues

**CereLink® ICP Monitor**

Advanced digital ICP monitoring platform for neuro-intensive care

**Certas® Plus Programmable Valve**

Implantable programmable valve for managing hydrocephalus

**Aurora® Surgiscope System & MIS**

Tubular retractor system to manage intracerebral hemorrhage

**Mayfield® Cranial Stabilization**

Surgical device to stabilize the patient's head during procedures

### We Deliver Broader and Deeper Solutions



1. **Addresses complex pathologies and disease states** in neurosurgery and surgical adjacencies
2. **Portfolio** spans the entire continuum of care from pre-operative stabilization to post-operative neuro-critical care
3. **Industry-leading sales channel** that offers a full portfolio of solutions to specialized customers and surgeons at multiple care sites

CSF = Cerebrospinal Fluid; ICP = Intracranial Pressure; MIS = Minimally Invasive Surgery

# ENT and Instruments

## High-precision ENT and laparoscopic manual instruments

**ENT**

**TruDi® Navigation System**

3D surgical navigation system utilized for complex ENT procedures

**Relieva Spinplus® Balloon Sinuplasty**

Balloon sinuplasty system for treating chronic sinusitis

**AERA® Eustachian Tube Dilation System**

Balloon dilation system for obstructive eustachian tube dysfunction

**MicroFrance® ENT instrumentation**

High-precision ENT and laparoscopic manual instruments

**Instruments**

**Jarit® Surgical Instruments**



**Ruggles®-Redmond™**

**OmniTract® Instruments**

**Surgical Lighting**

### We Deliver Broader and Deeper Solutions

1. Expansion of evolution of ENT business **from manual instrumentation to high-tech platform offerings** following the Acclarent acquisition

2. **Instruments** is an acute care division focused on general, specialty instruments and lighting portfolio

3. **Surgical instrument portfolio** that caters to central sterile processing units & acute surgical centers; and is delivered through direct and alternate site channels

# Integra is #1 or #2 in most categories in which we compete

## Global market position and trend by platform

| | Dural Access & Repair | Advanced Energy | Neurocritical Care | Hydrocephalus | ENT[1] | Instruments |
|---|---|---|---|---|---|---|
| INTEGRA Market Position | #1 | #2 | #1 | #1 | #3 | #1 |
| LTM Q2'26A Revenue[2] | $0.3B | $0.2B | $0.1B | $0.2B | $0.1B | $0.2B |
| Other Players | Baxter, natus, B BRAUN SHARING EXPERTISE, STERIS, Medtronic, stryker | | | | | |

*Durable hospital and neurosurgeon relationships that sustain market leadership*

[1] US position for core ENT market; [2] LTM revenue as of 06/30/26

# Accelerate growth

## Prioritizing longer-term organic growth

### Specialty Surgery

**Libertís Shunt & EVD Catheters**

Combine antimicrobial / anti-occlusive tech

**Aurora**

Next-gen visualization platform
(4K resolution & fluorescence capability)

**CUSA Platform Expansion**

Extend current platform life with next gen solutions

**AERA 2.0 – Low Profile**

Expand adoption with a pediatric-focused eustachian tube device

# Specialty Surgery: Addressing complex pathologies in neurosurgery & surgical adjacencies

## Specialized customers

- Pediatric & Adult Neurosurgeons
- Neurointensivists (MD, NP)
- Affiliated specialty surgeons

## Multiple sites of care & call points

- Hospital OR
- Hospital ICU
- ASC

## INDUSTRY-LEADING SALES CHANNEL

Direct Sales Teams

- **US Neuro**

- **US ENT**

- **US Instruments**

- **International**[1]
  - EMEA
  - Canada
  - China
  - Japan

**Resource, time intensive process & sales cycle** that includes opportunity creation, evaluation, capital sales process navigation & installation / support

Portfolio breadth provides a **competitive advantage in customer relationship management**, supply allocations, and territory management

**Sustain market leadership positions** in key segments, while targeting strategic growth and conversion opportunities

[1] Key international direct markets

# Category-leading technologies fueled by scale and resilience




| % growth | 2021A | 2022A | 2023A | 2024A | 2025A | YTD 06/30 2025 | YTD 06/30 2026 |
|---|---|---|---|---|---|---|---|
| Total Specialty Surgery | 14.6% | (0.6%) | 3.9% | 8.0% | 5.0% | 4.7% | 1.3% |
| ENT | - | 2.7% | 13.4% | NM | NM | NM | (2.2%) |
| Instrument | 6.6% | 1.3% | 5.7% | 0.3% | 1.1% | 5.5% | (1.9%) |
| Neuro | 12.1% | (1.1%) | 3.0% | (1.7%) | 3.0% | (2.1%) | 2.9% |

**2021**
- Double-digit growth driven by recovery of deferred neurosurgery and instrument volumes following COVID

**2022**
- Second wave of COVID-impacted neurosurgery volumes

**2023**
- Core neurosurgery demonstrates resilience

**2024**
- Acquired scaled ENT business through Acclarent acquisition
- Impact of quality holds and initiate compliance master plan

**2025**
- Building a foundation of supply and execution to solidify long-term market leadership

**YTD 2026**
- Specialty Surgery is transitioning from recovery-driven performance toward a more normalized market growth profile

03

# Tissue Reconstruction

INTEGRA

# Tissue Reconstruction Overview

## Poised for Growth in Attractive Global Markets

**~$2.5B** Market

**~$0.4B** Revenue[1]

**~90%** Of sales are to the hospital and surgery center setting

### WOUND RECONSTRUCTION ("WR")
MSD Market CAGR

**COMPLEX WOUNDS, BURNS, TRAUMATIC, CHRONIC WOUNDS, NERVE AND TENDON REPAIR**

**Wound Reconstruction Solutions**

*Integra® Dermal Matrices • PriMatrix • MicroMatrix • Cytal® AmnioExcel® • MediHoney® • TCC-EZ • NeuraGen*

### SOFT TISSUE SOLUTIONS
MSD to HSD Market CAGR

**SOFT TISSUE AND MUSCLE FLAP REINFORCEMENT, BREAST RECONSTRUCTION, HERNIA REPAIR**

**Soft Tissue Solutions**

*SurgiMend • DuraSorb® • Gentrix®*

### PRIVATE LABEL
MSD Growth

**B2B PARTNERSHIPS WITH SELECT COLLAGEN TECHNOLOGIES**

**Private Label Partners**

Note: Market size and growth from third party market reports and internal estimates; [1] LTM revenue as of 06/30/26

# Wound Reconstruction Solutions

## Comprehensive portfolio to treat complex wounds

**Engineered Collagen (Integra®)**

Helps Restore Lost *Function* and Joint Mobility

**Fetal Bovine Collagen (PriMatrix®)**

An *Adaptable* Solution for Challenging Wounds

**Placental Allograft (AmnioExcel®)**



*Strong* Enough to go the Distance

**UBM (MicroMatrix® & Cytal®)**

*Addressing* Challenging Wound Microenvironments

**We Deliver Broader and Deeper Solutions**

1. Complex wound reconstruction can be difficult, **surgeons need choices** to address how wounds may be uniquely presenting

2. **Integra LifeSciences offers a broad portfolio** addressing a full spectrum of needs when managing complex wounds

3. **Integra's specialized wound care sales team** delivers a full portfolio to meet surgeon and patient needs

UBM = Urinary Bladder Matrix

# Soft Tissue Solutions

## Comprehensive portfolio for soft tissue reinforcement and repair

**SurgiMend Biological Matrix**



Source Material: Fetal Bovine Dermis
Category: **Xenograft Biologic**
**Meshed/Fenestrated** and **Surgical/Hiatal** configurations

**DuraSorb® Monofilament Mesh**

Source Material: Polydiaxanone
Category: **Bioresorbable Synthetic**
Macroporous/Monofilament Mesh

**Gentrix® Surgical Matrix**

Source Material: UBM
(Urinary Bladder Matrix)
Category: **Xenograft Tissue Scaffold**
**Surgical/Hiatal** configurations

**We Deliver Broader and Deeper Solutions**

1. Flagship collagen-based products exhibit biological superiority and are associated with **fetal-like healing, rapid tissue remodeling, and superior elasticity**
2. Broad portfolio that **covers high-incidence surgical needs** from complex ventral hernia reconstruction to specialized breast procedures
3. **Pursuing "first-mover" advantage** in the IBBR market by seeking formal PMA approval for both its biologic and synthetic platforms

IBBR = Implant-Based Breast Reconstruction; PMA = Pre-market approval; UBM = Urinary Bladder Matrix

# Integra is #1 in Wound Reconstruction and an emerging competitor in Soft Tissue Solutions

## Global market position and trend by platform (excl. private label[1])

| | Wound Reconstruction Solutions | Soft Tissue Solutions |
|---|---|---|
| INTEGRA Market Position | *#1* | *#7* |
| LTM Q1'26 Revenue | *$0.3B* | *<$0.1B[2]* |
| Other Players | Smith+Nephew, LifeNet Health, ORGANOGENESIS, Kerecis, MIMEDX | abbvie / LifeCell, BD, mtf biologics, stryker |

*We continue to be a top key market player in the tissue reconstruction subsegments*

Note: Tissue Reconstruction market positions are hospital-based and do not include office-based procedures
[1] Q1'26 LTM revenue of $113M; [2] Excludes SurgiMend®; anticipated relaunch in 4Q'26

# Accelerate growth

## Prioritizing four strategies to deliver innovation and drive organic growth

**Tissue Reconstruction**

### Implant Based Breast Reconstruction

Drive adoption via dual-PMAs of SurgiMend and DuraSorb

SurgiMend and DuraSorb PMAs expected to be approved in 2027

### Wound Reconstruction Outpatient (OP)

Capitalize on CMS reimbursement changes

### PriMatrix & SurgiMend

Rapidly recover pre-recall revenue and grow market share

UBM = Urinary Bladder Matrix

# Tissue Reconstruction: Leading the way in regenerative and tissue technologies

## Multiple sites of care & call points

- Hospital Inpatient & Outpatient ORs
- Wound Care Clinics
- ASCs
- Physician Offices

## Specialized customers

- Plastic & Reconstructive surgeons
- Podiatric surgeons
- General & Trauma surgeons
- Vascular & Orthopedic surgeons

## INDUSTRY-LEADING SALES CHANNEL

Direct Sales Team

Sales teams are organized around physician specialties to foster **deep clinical expertise and dedicated relationships** with surgeons

Leverage long-standing hospital presence and comprehensive GPO relationships of neurosurgery business **to gain account access and drive tissue product adoption**

Portfolio breadth, centered around industry's broadest regenerative platform, **drives tailored solutions for clinical partners** spanning a broad continuum of patient care

# CMS Reimbursement Reform

## 2026 CMS Wound Care Reimbursement Reform is expected to be a Net Positive for Integra

| What CMS Changed (Context) | Why This Benefits Integra (Impact) |
|---|---|
| CMS significantly reduced reimbursement rates for skin substitutes beginning January 1, 2026, from an **average ASP of ~$1,300/cm²** **(across 200+ skin substitutes) to ~$127/cm²** | Integra's portfolio is **already priced under ~$127/cm²** – no price or margin risk on existing or incremental volume |
| Reforms are intended to **address overuse and excessive reimbursement** of skin substitutes in physician office settings | Integra is well positioned commercially to **capture volume shifting away from physician offices** |
| New economics and oversight should result in procedures shifting **out of physician offices and into inpatient (hospital) settings** | **~90% of Integra's revenue is hospital based**, reimbursed under a diagnosis-related group (DRG) and **not exposed to the January 1 CMS reimbursement changes** |
| **Manufacturers with significant physician office volume face meaningful margin pressure** under the new reimbursement economics | Broad portfolio, strong clinical evidence, and appropriate pricing **uniquely positions Integra across inpatient and outpatient settings** |

# 2026 recovering from previous operational headwinds




| % growth | 2021A | 2022A | 2023A | 2024A | 2025A | YTD 06/30 2025 | YTD 06/30 2026 |
|---|---|---|---|---|---|---|---|
| Total Tissue Reconstruction | 8.4%[1] | 4.0% | (9.9%) | (3.3%) | (6.9%) | (6.6%) | 2.2% |
| WR | 27.9%[1] | 5.8% | (5.6%) | (6.2%) | (7.9%) | (5.4%) | 0.9% |
| Private label | 34.6%[1] | (0.6%) | (23.3%) | 6.5% | (4.0%) | (10.0%) | 6.1% |

**2021**
- Acquisition of ACell's porcine urinary bladder matrix platform and divestiture of Extremity Orthopedics business
- Portfolio focused in high-margin regenerative tissue

**2022**
- Segment hits an all-time high in revenue
- Performance driven by Integra Skin and ACell MicroMatrix
- Divestiture of Traditional Wound Care business

**2023**
- Mid-year Boston facility product recall (including SurgiMend and PriMatrix) created a temporary headwind to revenue

**2024**
- Full year impact of the Boston facility recall and supply constraints in key collagen-based products

**2025**
- Improvements in Integra Skin capacity and yield
- Relaunch PriMatrix
- MediHoney recall

**YTD 2026**
- Growth trajectory stabilizing toward market levels, while advancing the Braintree start up and preparing for the SurgiMend relaunch

[1] 2021A growth rates reflect a recovery from pandemic-related contractions in 2020 due to global surgical procedure deferrals

04

# Supply Chain / Operations

INTEGRA

# Global manufacturing and distribution footprint

## Global network that supports broad technology portfolio throughout patient journey


| 17 | 3 | 9 |
|---|---|---|
| *Established manufacturing sites* | *Primary global 3rd-party logistics distribution centers* | *Local country distribution centers (3PL and ILS owned)* |

# Overview of state-of-the-art facilities

Top 4 sites

## ANASCO, PUERTO RICO



- Competencies: Collagen manufacturing & packaging, device assembly & packaging
- ISO7/ISO8 Clean rooms
- Space: ~80k sq. ft.
- Areas of focus: Dural Access & Repair, Regenerative Neurosurgery

## PLAINSBORO, NEW JERSEY

- Competencies: Collagen manufacturing & packaging
- ISO7 Clean rooms
- Space: ~84k sq. ft.
- Areas of focus: Advanced Wound Care, Dermal Regeneration

## LE LOCLE, SWITZERLAND

- Competencies: Micro molding & assembly, antibiotics impregnation, packaging
- ISO8 Clean rooms
- Space: ~ 80k sq. ft
- Areas of focus: Cerebral Spinal Fluid (CSF) Management, Neurosurgical Monitoring

## BRAINTREE, MASSACHUSETTS

- Competencies: Bovine Matrix processing & packaging
- ISO8 Clean rooms
- Space: ~107k sq. ft.
- Areas of focus: Surgical Reconstruction, Plastic & Reconstructive Surgery

Operational since June 2026

***A broad manufacturing footprint with distinct, specialized capabilities creates a durable competitive advantage***

# Key Capabilities to Drive Operations and Customer Excellence



# Summary of global operations opportunity

**Milestones**

**Mid-60%**
Return to historical GM

**95%+**
sustained service levels

**5%+**
productivity improvement annually

1. **Return to Historical GM**
   *Enhanced gross margins and improved cashflow*
2. **Sustained Service Levels**
   *Product quality consistency and performance predictability*
3. **Productivity Improvement Annually**
   *Improved production yields and order cycle items*

05

# Remediation update

INTEGRA

# Beyond Remediation: Building a Stronger Quality and Operating Foundation

## Warning Letter Timeline

***2019 Warning Letter (Boston Facility)***
- *CAPA systems, validation of manufacturing processes, endotoxin testing*

***2023 Warning Letter (Boston Facility)***
- *Manufacturing controls, documentation relating to endotoxin testing*

***2024 Warning Letter (three sites)***
- *Environmental monitoring, sterilization revalidation, CAPA processes*

***Additional Field Actions***
- *Class I recalls of CODMAN Disposable Perforators and Extended Tip Applicators, and Class II recalls of MediHoney and Tuohy Needle kits*

| | FOCUS AREA | IMPROVED OUTCOMES |
|---|---|---|
| Quality | Remediation of Quality System Gaps | • Addressing FDA observations from Form 483s and Warning Letters<br>• Sterilization requalification and test method validation<br>• **Site-level assessments** and **targeted workstreams** |
| Supply Chain | Facility Investments | • New 10,000 sq. ft. designed to implement more effective quality management systems (QMS) and **restore supply for** SurgiMend and PriMatrix<br>• Dual-sourcing strategy to mitigate rev. loss during Braintree build-out, to relaunch PriMatrix and Durepair in Oct 2025<br>• Capacity and Productivity investments at our Plainsboro and Le Locle facilities |
| | QMS Harmonization | • Standardizing quality processes across all 17 global mfg. sites<br>• Replace fragmented, site-specific procedures with a standardized enterprise QMS<br>• Unified CAPA escalation logic |
| Execution | Culture Enhancement | • Disciplined program management<br>• Effective prioritization<br>• Instituted robust training and development program with site level engagement |
| | Operational Oversight | • Mgmt. has established the Transformation and Program Management Office (TPMO)<br>• Supply Chain Control Tower to provide daily visibility into operational metrics and manufacturing yields across all facilities |

***All activities required to address warning letter observations on track to be implemented by end of 2026***

# Path to full product reintroduction

*Relaunch completed*

| Products | Current Status |
|---|---|
|  Cranial perforators | ✓ **Relaunched** |
|  PriMatrix® Dermal Scaffold | ✓ **Relaunched** |
|  Durepair® Dura Regeneration Matrix | ✓ **Relaunched** |
|  SurgiMend® | • Anticipated relaunch in 4Q'26 from the Braintree, MA facility |
|  CODMAN® Cottonoid® Surgical Strips and Patties | • Remediation in process to support release with streamlined product portfolio |
|  MediHoney® Wound & Burn Dressing | • Remediation in process with 3rd party manufacturer to support 2027 release |

***All products, which historically represented ~$150mm of annual revenue, are expected to be reintroduced to market by the end of 2027***

# Braintree: restoring supply and enabling recovery

**A new, purpose-built site replacing Integra's legacy Boston manufacturing operation — restoring in-house supply of key products, with start-up delivered on the committed timeline**

## BRAINTREE, MASSACHUSETTS

**Operational & producing since Q2 2026**

## FROM COMMITMENT TO DELIVERY

| Milestone | What management committed to | Status |
|---|---|---|
| PriMatrix & Durepair | Restore supply via alternate supplier | ✓ Relaunched in Q4 2025 — ~12 months ahead of plan |
| Facility start-up | Braintree online by end of June 2026 | ✓ Online and producing inventory in Q2 2026 — on time |
| SurgiMend relaunch | Return SurgiMend to market in Q4 2026 | On track: producing inventory to support the Q4 2026 relaunch |
| Transition-cost wind-down | Reduce transition costs as Braintree ramps | Expect transition costs to decline greater than 50% from 2025 to 2026 |

## Why Braintree matters to the IART story

**Restoring supply through disciplined execution**
Braintree's on-time start-up marks the completion of a major manufacturing reset, restoring supply and validating the effectiveness of management's recovery plan

**Provides the foundation for indication expansion**
Braintree will enable the launch of PMA products that will provide a differentiated advantage in implant-based breast reconstruction (IBBR)

**Supports the financial recovery**
With Braintree operational, remediation activities and associated special charges are expected to decline, supporting earnings, cash flow, and deleveraging

Source: Integra LifeSciences Q2 2026 earnings release and investor presentation (July 29, 2026); Q4 2025 (Feb 2026) and Q1 2026 (May 2026) earnings calls; company filings
Note: ✓ = delivered; remaining milestones onack as noted. Transition cost reflects the Braintree transition adjustment (adjusted net income basis). Dollar figures in USD millions

# Key adjustments mapped to Integra's story

## Trailing twelve months across meaningful categories

| (In $M) | 2024A | 2025A | LTM Q2'26A | Q1'26A | Q2'26A | COMMENTARY |
|---|---|---|---|---|---|---|
| EU MDR | 44.6 | 41.9 | 30.6 | 7.9 | 2.4 | • 90% complete, as we continue to reduce headcount of contractors working on EU MDR-related efforts with majority rolled off and Q2 figures reflecting normalized spend |
| Acquisition Related | 33.6 | 3.6 | (3.4) | 1.8 | 2.4 | • Acclarent integration costs winding down |
| Structural Optimization | 24.2 | 48.0 | 48.2 | 9.3 | 7.5 | • Include benefits of $5.3M, $20.5M, and $0.8M in 2024, 2025, and YTD 2026 for contingent consideration adjustments |
| Braintree Transition | 45.0 | 56.2 | 45.4 | 7.7 | 9.9 | • Expected to come down in near term, driven by a reduction in idle manufacturing costs incurred during the production remediation period |
| **Operating Non-GAAP Adjustments** | **$147.4** | **$149.7** | **$120.8** | **$26.7** | **$22.3** | • Braintree became operational at the end of June 2026, allowing for transition-related expenses to be significantly reduced by end of 2026; on-track to launch SurgiMend and generate commercial revenue in Q4 2026 |

***Substantial reduction between EU MDR and Braintree underpin significant operating cash flow improvement***

06

# Investment highlights

INTEGRA

# Sustained category leadership and operational excellence

1. Global player with leading positions in neurosurgery and regenerative medicine
2. Large and growing addressable markets
3. Diversified portfolio across neurosurgery, reconstructive, and general surgical specialties
4. Strong clinical brand equity and surgeon loyalty supported by differentiated product performance and clinical evidence
5. Clear and methodical remediation plan well underway and supported by significant investment
6. At key inflection point with visibility to return to strong FCF generation and deleveraging
7. Seasoned leadership team with decades of MedTech experience

# 1 Global leader in neurosurgery and regenerative medicine

## Advancing transformational care, delivering impactful innovation, and enriching life moments

### 1 NEUROSURGERY LEADERSHIP

- Holds #1 / #2 share in every served neuro category
- Deeply embedded in high-complexity, life-saving surgical workflows
- Strong brand equity and product differentiation backed by decades of clinical trust

### 2 REGENERATIVE MEDICINE PIONEER

- First FDA-approved dermal regeneration platform
- IDRT remains the gold standard for severe burns
- Proprietary engineered collagen platform (DuraGen, NeuraGen, NeuraWrap) extends into peripheral nerve and tendon repair


### 3 SPECIALIZED COMMERICIAL ENGINE

- Tenured salesforce in ~120 countries acts as indispensable clinical partners to surgeons
- RCT investment supports differentiation and pricing power
- High switching costs from clinical workflow integration

### 4 NEAR-TERM STRATEGIC CATALYSTS

- Pursuing "first-mover" advantage in the IBBR[1] market by seeking formal PMA approval for both its biologic and synthetic platforms
- Acclarent integration adds $1B TAM in high-growth ENT market
- Capitalize on favorable CMS reimbursement changes to level CTP[2] playing field

[1] IBBR = Implant-Based Breast Reconstruction; [2] CTP = Cell & Tissue-Based Products (i.e. skin substitutes)

# 2 Large and growing addressable markets

## Global Opportunity


## Specialty Surgery


Neuro


ENT


Instruments

## Tissue Reconstruction


Wound Reconstruction Solutions


Soft Tissue Solutions


Private Label

[1] TAM excludes private label markets

# 3 Diversified portfolio across various specialties

## Specialty Surgery

### Neuro


Duragen Dural Graft Matrix


Aurora Surgiscope


CUSA Tissue Ablation


Duraseal Dural Sealant


CereLink® ICP Monitor and Sensors


BACTISEAL Catheters


Certas Plus Programmable Valves

## Tissue Reconstruction[1]

### Wound Reconstruction Solutions


Integra Dermal Matrices


AmnioExcel®


PriMatrix


MediHoney


MicroMatrix


TCC-EZ®


Cytal®


NeuraGen®

## ENT


TruDi® Navigation System


RELIEVA SPINPLUS® Balloon Sinuplasty System


AERA® Eustachian Tube Dilation System


MicroFrance ENT instrumentation

## Instruments


Jarit


DUO LED Surgical Headlight

## Soft Tissue Solutions


SurgiMend


DuraSorb


Gentrix

[1] Excludes private label

# 4 Significant brand equity and loyalty

## Highly differentiated products trusted by healthcare professionals and systems

### Clinically differentiated products

- "First-to-market" innovations, especially in dural repair and ultrasonic tissue ablation
- Outcome reliability establishes brand as a risk-mitigating choice
- High brand recall among neurosurgeons and reconstructive specialists
- Core products function as default selection within key indications


### Training-led adoption model

- Incumbency advantage reinforced in time-sensitive surgical settings
- Surgeon muscle memory and technique standardization limit substitution
- Deep adoption across leading academic and tertiary care centers
- On-demand learning resources for HCPs through Integra Institute

### Partnership ethos

- Comprehensive onboarding, training, and change management support
- Proactive post-market engagement rather than transactional vendor relationships

# 5 Clear and methodical remediation plan well underway

## Strengthening the foundation to enable a reliable & scalable supply chain

| Key Focus Areas | | Roadmaps and Targets |
|---|---|---|
| **Quality**<br>• Embedding a quality culture to drive results and continuous improvement<br>• Delivering on key metrics<br>• Develop supplier management and stabilization program<br>• Remediating sites<br>• Driving EU MDR product compliance | **Operations**<br>• Implementing full production process ownership & org redesign<br>• Driving increased alignment with Good Manufacturing Practices<br>• Deploying Lean & Six Sigma<br>• Planning and executing Integrated Business Planning<br>• Increasing visibility and planning via Supply Chain Control Tower<br>• Enhancing process capabilities | **Quality transformation and site/ production remediation**<br><br>**Supply chain improvement and IBP roadmap** |

***Robust governance in place to ensure resourcing and milestone achievement***

# 6 Return to strong FCF generation and deleveraging

## Strong Free Cash Flow to support meaningful deleveraging story







Drivers of Margin Expansion & Cash Flow Improvement

- **Return Products to Market** through completion of remediation activities
- **Deliver Cost Savings Initiatives** announced and implemented in Q1 2026 as part of a broader margin expansion program
- **Simplify Operations** through the new operating model, improving efficiency and accountability
- **Eliminate Temporary Transformation Costs** as EU MDR, Braintree start-up, and structural optimization expenses roll off
- **Improve Working Capital Performance** through better inventory and receivables management
- **Expand Gross Margins** through lower remediation costs, reduced scrap, and manufacturing productivity gains
- **Normalize Capital Spending** as major investments in Braintree and capacity expansion are completed

[1] GAAP net cash provided by operating activities, net of CapEx. Free Cash Flow is a non-GAAP measure. See appendix for non-GAAP reconciliation
[2] Debt includes undrawn Letters of Credit and non-contingent deferred payment obligations (including certain deferred purchase price obligations and earned but unpaid earn-outs), excluding ordinary-course trade payables

# 7 Seasoned leadership team with decades of MedTech experience

## Executive Leadership


Stuart Essig, Ph.D.
*President and CEO*


Andrea Caruso
*Corporate VP, Strategy & Business Development*


Robert T. Davis, Jr.
*President, Tissue Reconstruction*


Kerri DiPietro
*Corporate VP, Chief Quality Officer*


Teshtar Elavia
*Corporate VP, CTO*


Michael Hutchinson
*EVP, CLO, Company Secretary*


Topaz Kirlew
*Chief Regulatory Officer*


Lea Daniels Knight
*Chief Financial Officer*


Dimitri Kvares
*CVP, CIO*


Rick Maveus
*SVP, Transformation & Program Management*


Michael McBreen
*EVP & Chief Commercial Officer*


Harvinder Singh
*EVP & President, International*


Dr. Raymond Turner
*Corporate VP & CMO*


Chantal Veillon
*EVP & CHRO*


Valerie Young
*Corporate VP, Global Operations & Supply Chain*

3M · Lilly · Johnson&Johnson · Boston Scientific · Baxter · Medtronic · GE HealthCare · HAEMONETICS

## Board of Directors


Stuart Essig, Ph.D.
*President and CEO*


Keith Bradley, Ph.D.


Shaundra Clay


Barbara B. Hill


Jeff Graves, Ph.D.


Renee Lo


Christian Schade

Google · Microsoft · HALDA · Teleflex · 3D SYSTEMS · St. Jude Medical

| *Leadership* | *Organization* | *Execution* |
|---|---|---|
| *Deep and specialized MedTech expertise* | *Structural alignment and enhanced accountability* | *Delivering on operational and financial Compliance Master Plan* |

07

# Financial summary

INTEGRA

# Financial policy

**Balance Sheet**

- Continue to prioritize optimizing the Company's capital structure with a focus on deleveraging, extending maturities, and maintaining adequate liquidity
- Decreased net leverage from 4.5x (2025YE) to 4.1x (Q2'2026)
  - Our target net leverage ratio is 2.5-3.5x
- Disciplined portfolio investments with a focus on high-growth, high-margin opportunities that we have a clear right-to-win position in

**Strategic Investments**

**Capital Expenditures**

- Remediation and project costs expected to be completed in fiscal year 2026
- Braintree facility became operational in Q2 2026; on track for commercial revenue being generated in Q4 2026
- 80% of CapEx focused on improving supply reliability and capacity with remaining 20% focused on growth and innovation

**M&A**

- Focus on deleveraging
- M&A strategy focused on tuck-ins following deleveraging and sustainable cash flow generation

**Capital Management**

**Liquidity**

- We anticipate increased flexibility to reduce outstanding Revolving Credit Facility borrowings as free cash flow generation improves, enhancing future borrowing capacity

**Share Repurchases**

- Repurchase shares strategically when it's the best way to return cash to our shareholders and when not in conflict with deleveraging objective
- Current program expired in Q4 2025 and has not been renewed

# Historical operating performance

## Revenue ($M)




## Compliance adjusted EBITDA ($M)[1]


## Capital expenditures




## Free cash flow[2]




Source: Company Filings
[1] Compliance adjusted EBITDA is a non-GAAP measure. See appendix for non-GAAP reconciliation;
[2] GAAP net cash provided by operating activities, net of CapEx. Free Cash Flow is a non-GAAP measure. See appendix for non-GAAP reconciliation

# Historical credit metrics













Source: Company Filings
Note: Debt includes undrawn Letters of Credit and non-contingent deferred payment obligations (including certain deferred purchase price obligations and earned but unpaid earn-outs), excluding ordinary-course trade payables
[1] Compliance adjusted EBITDA is a non-GAAP measure. See appendix for non-GAAP reconciliation;
[2] GAAP net cash provided by operating activities, net of CapEx. Free Cash Flow is a non-GAAP measure. See appendix for non-GAAP reconciliation

08

# Appendix

INTEGRA

# EBITDA reconciliation

## Trailing twelve month EBITDA reconciliation

| (In $M) | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | LTM Q2'26 |
|---|---|---|---|---|---|---|
| **Total Revenue** | **$1,542** | **$1,558** | **$1,542** | **$1,611** | **$1,635** | **$1,648** |
| **GAAP Net Income** | **$169** | **$181** | **$68** | **$(7)** | **$(516)** | **$(7)** |
| Goodwill impairment charges | - | - | - | - | 511 | - |
| Depreciation and intangible asset amortization expense | 123 | 118 | 123 | 147 | 151 | 152 |
| Other (income), net | (14) | (8) | (3) | (4) | 3 | (8) |
| Interest expense, net | 44 | 38 | 34 | 51 | 66 | 73 |
| Income tax expense (benefit) | 46 | 33 | 13 | (11) | (47) | 7 |
| Structural optimization charges | 20 | 23 | 16 | 24 | 48 | 48 |
| EU Medical Device Regulation charges | 24 | 45 | 47 | 45 | 42 | 31 |
| Boston Recall | - | - | 47 | 45 | 56 | 45 |
| COVID-19 related charges | - | - | - | - | - | - |
| Convertible debt non-cash interest | - | - | - | - | - | - |
| Expenses related to debt refinancing | - | - | - | - | - | - |
| Discontinued product lines charges | 0 | - | - | - | - | - |
| Acquisition, divestiture and integration-related charges | (12) | (19) | 25 | 34 | 4 | (3) |
| **Total of non-GAAP adjustments** | **232** | **231** | **302** | **329** | **834** | **345** |
| **Adjusted EBITDA** | **$401** | **$411** | **$370** | **$322** | **$317** | **$337** |
| *Adjusted EBITDA Margin* | *26.0%* | *26.4%* | *24.0%* | *20.0%* | *19.4%* | *20.5%* |
| Stock-based compensation | 36 | 25 | 20 | 24 | 19 | 25 |
| Interest income | 7 | 12 | 17 | 20 | 18 | 18 |
| Other income | 61 | 13 | 4 | (1) | (2) | 8 |
| Other credit facility adjustments | (47) | (9) | (10) | 23 | 6 | 8 |
| **Total Credit Agreement adjustments** | **57** | **41** | **31** | **66** | **41** | **59** |
| **Compliance adjusted EBITDA** | **$458** | **$452** | **$401** | **$389** | **$359** | **$396** |
| *Compliance Adjusted EBITDA Margin* | *29.7%* | *29.0%* | *26.0%* | *24.1%* | *21.9%* | *24.1%* |

# FCF & Adjusted Gross Margin reconciliation

## Trailing twelve month FCF reconciliation

| (In $M) | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | LTM Q2'26 |
|---|---|---|---|---|---|---|
| **Operating Cash Flow** | **$312** | **$264** | **$140** | **$129** | **$50** | **$85** |
| Capex | 48 | 42 | 67 | 104 | 81 | 60 |
| **Free Cash Flow** | **$264** | **$222** | **$73** | **$25** | **$(31)** | **$26** |

## Trailing twelve month Adjusted Gross Margin reconciliation

| (In $M) | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | LTM Q2'26 |
|---|---|---|---|---|---|---|
| **Total Revenue** | **$1,542** | **$1,558** | **$1,542** | **$1,611** | **$1,635** | **$1,648** |
| **GAAP Gross Profit** | **$945** | **$970** | **$885** | **$882** | **$832** | **$865** |
| Structural optimization charges | 9 | 6 | 8 | 16 | 28 | 24 |
| Acquisition, divestiture and integration-related charges | 20 | 2 | 3 | 9 | 1 | 0 |
| Braintree transition | - | - | 46 | 43 | 55 | 44 |
| EU MDR | 4 | 5 | 6 | 4 | 4 | 3 |
| Intangible asset amortization expense | 67 | 64 | 70 | 84 | 92 | 93 |
| **Total of non-GAAP adjustments** | **99** | **76** | **134** | **156** | **180** | **165** |
| **Adjusted Gross Profit** | **$1,043** | **$1,046** | **$1,018** | **$1,038** | **$1,012** | **$1,029** |
| *Adjusted Gross Margin* | *67.7%* | *67.2%* | *66.1%* | *64.5%* | *61.9%* | *62.5%* |